menu
    • menu
    [{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Red Queen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"RQ-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Red Queen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Red Queen Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dana-Farber Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hale Family Center for Pancreatic Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Dana-Farber Cancer Institute

    Menu

    Dana-Farber Cancer Institute

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEO-PV-01,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cancer Vaccine Shows Promise for Patients with Stage III and IV Kidney Cancer

                            Details : NeoVax is a combination of neoantigen peptides and poly-ICLC which is being evaluated in combination with ipilimumab for the treatment of renal cell carcinoma.

                            Product Name : NeoVax

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 06, 2025

                            Lead Product(s) : NEO-PV-01,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RQ-01

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Red Queen Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Red Queen Expands License Agreement, Advances Pan-Influenza Program

                            Details : Dana-Farber grants Red Queen exclusive license to stapled lipopeptide COVID-19 therapeutics, incorporates additional exclusive patent rights covering RSV therapeutics.

                            Product Name : RQ-01

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : RQ-01

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Red Queen Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Hale Family Center for Pancreatic Cancer Research

                            Deal Size : $80.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Dana-Farber Receives $50 million Funding to Study Pancreatic Cancer

                            Details : Funding will enable a wide range of ambitious work in two main areas of pancreatic cancer research: early detection and prevention, and precision medicine and biology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 05, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Hale Family Center for Pancreatic Cancer Research

                            Deal Size : $80.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirogacestat Hydrobromide,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : SpringWorks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SpringWorks Therapeutics Enters Into Research Collaboration with Leading Cancer Institute to Evaluate Nirogace...

                            Details : The collaboration is designed to further investigate nirogacestat, SpringWorks’ investigational gamma-secretase inhibitor (GSI), with anti-B-cell maturation antigen (BCMA) agents in a variety of preclinical multiple myeloma models.

                            Product Name : PF-03084014

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 30, 2021

                            Lead Product(s) : Nirogacestat Hydrobromide,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : SpringWorks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paxalisib

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Kazia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

                            Details : The collaboration aims at investigating the use of Kazia’s new drug, paxalisib (formerly GDC-0084), in primary central nervous system (CNS) lymphoma, a potential new indication for the drug. DFCI will initiate an open-label phase II clinical trial of p...

                            Product Name : GDC-0084

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : Paxalisib

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Kazia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brexucabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dana-Farber to Offer First CAR T-cell Therapy for Mantle cell Lymphoma Following FDA Approval

                            Details : Approval of Tecartus was based on the results of the ZUMA-2 clinical trial, which involved 74 adult patients with mantle cell lymphoma that had relapsed or become resistant to several prior lines of therapy.

                            Product Name : Tecartus

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 24, 2020

                            Lead Product(s) : Brexucabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed

                            Dana-Farber Cancer Institute

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAR T-Cell Therapy Found Highly Effective in Patients with High-Risk Non-Hodgkin Lymphoma

                            Details : In the current trial, dubbed ZUMA-5, investigators administered axi-cel to 146 patients with follicular lymphoma or marginal zone lymphoma-two slow-growing forms of non-Hodgkin leukemia-at multiple U.S. medical centers.

                            Product Name : Yescarta

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 12, 2020

                            Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth